GlassScriptPhysician profile
Tamara A Parrish
NPI 1316111727
$1,541.37
in general payments reported to CMS, 2019-2025
20 companies · $733 in 2025
The $733 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $35.42 · 2022: $127 · 2023: $36.50 · 2024: $610 · 2025: $733.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,379.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,379.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $473.07 | 2021-2025 | |
| Novo Nordisk INC | $300.80 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Sumitomo Pharma America, INC. | $103.07 | 2024-2025 | Gemtesa |
| Astrazeneca Pharmaceuticals LP | $93.90 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Otsuka America Pharmaceutical, INC. | $92.39 | 2024-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $75.69 | 2025 | Caplyta |
| Abbott Laboratories | $57.22 | 2021-2022 | |
| Exact Sciences Corporation | $53.52 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $40.85 | 2024 | Trelegy Ellipta, Arexvy |
| Lilly USA, LLC | $34.74 | 2022-2025 | Mounjaro, Zepbound |
| Neurocrine Biosciences, INC. | $31.95 | 2025 | |
| Axsome Therapeutics, INC. | $28.73 | 2025 | Auvelity |
| Lundbeck LLC | $23.13 | 2025 | Rexulti |
| Jazz Pharmaceuticals INC. | $22.94 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.40 | 2025 | Xifaxan |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $20.34 | 2024 | Voquezna |
| Corcept Therapeutics | $19.66 | 2025 | Korlym |
| Teva Pharmaceuticals USA, INC. | $17.46 | 2023 | Austedo Xr |
| Sunovion Pharmaceuticals INC. | $16.66 | 2022 | |
| Vanda Pharmaceuticals INC. | $14.85 | 2024 | Fanapt, Hetlioz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Parrish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.